Circulating tumor DNA as a predictor of treatment response to neoadjuvant chemotherapy in stage 2/3 rectal cancer without high risks: Subset analysis from the COPEC trial. Circulating tumor DNA (ctDNA ...
CHICAGO--(BUSINESS WIRE)--Today NOCD, the #1 telehealth provider for the treatment of obsessive-compulsive disorder (OCD), announced the results of the industry’s largest peer-reviewed retrospective ...
Phase II study of weekly paclitaxel and carboplatin followed by oral navelbine in patients with triple negative metastatic/recurrent breast cancer previously treated with adjuvant anthracycline and ...